Clinical Study
Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19
Figure 2
The distribution of lymphocytes in the healthy control group (HC) and COVID-19 patients at each period in (a) the glucocorticoid group and (b) the nonglucocorticoid group. The distribution of CD3+ T cells in the healthy control group (HC) and COVID-19 patients at each period in (c) the glucocorticoid group and (d) the nonglucocorticoid group. The distribution of CD4+ T cells in the healthy control group (HC) and COVID-19 patients at each period in (e) the glucocorticoid group and (f) the nonglucocorticoid group. The distribution of CD8+ T cells in the healthy control group (HC) and COVID-19 patients at each period in (g) the glucocorticoid group and (h) the nonglucocorticoid group.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |
(h) |